Trade Morphosys AG - MOR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.28 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.022099% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.000123% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | EUR | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | Germany | ||||||||
| Commission on trade | 0% |
| Prev. Close | 67.61 |
| Open | 67.66 |
| 1-Year Change | 244.85% |
| Day's Range | 67.61 - 67.66 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2024 | 67.61 | 0.00 | 0.00% | 67.61 | 67.61 | 67.61 |
| Apr 23, 2024 | 67.61 | 0.00 | 0.00% | 67.61 | 67.76 | 67.61 |
| Apr 22, 2024 | 67.66 | 0.05 | 0.07% | 67.61 | 67.71 | 67.61 |
| Apr 19, 2024 | 67.56 | -0.05 | -0.07% | 67.61 | 67.61 | 67.56 |
| Apr 18, 2024 | 67.61 | 0.00 | 0.00% | 67.61 | 67.66 | 67.56 |
| Apr 17, 2024 | 67.61 | 0.05 | 0.07% | 67.56 | 67.66 | 67.56 |
| Apr 16, 2024 | 67.71 | -0.10 | -0.15% | 67.81 | 67.86 | 66.91 |
| Apr 15, 2024 | 67.81 | 0.05 | 0.07% | 67.76 | 67.86 | 67.71 |
| Apr 12, 2024 | 67.81 | 0.40 | 0.59% | 67.41 | 67.86 | 67.41 |
| Apr 11, 2024 | 67.46 | 0.45 | 0.67% | 67.01 | 67.46 | 67.01 |
| Apr 10, 2024 | 67.06 | 0.60 | 0.90% | 66.46 | 67.06 | 66.46 |
| Apr 9, 2024 | 66.96 | 0.30 | 0.45% | 66.66 | 67.01 | 66.66 |
| Apr 8, 2024 | 66.91 | 0.00 | 0.00% | 66.91 | 67.01 | 66.81 |
| Apr 5, 2024 | 66.96 | -0.05 | -0.07% | 67.01 | 67.11 | 66.91 |
| Apr 4, 2024 | 67.01 | 0.10 | 0.15% | 66.91 | 67.11 | 66.91 |
| Apr 3, 2024 | 67.11 | 0.05 | 0.07% | 67.06 | 67.16 | 67.06 |
| Apr 2, 2024 | 67.11 | 0.70 | 1.05% | 66.41 | 67.16 | 66.41 |
| Mar 28, 2024 | 67.11 | 0.00 | 0.00% | 67.11 | 67.13 | 67.11 |
| Mar 27, 2024 | 67.11 | 0.22 | 0.33% | 66.89 | 67.13 | 66.89 |
| Mar 26, 2024 | 67.09 | 0.04 | 0.06% | 67.05 | 67.13 | 67.05 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Morphosys Company profile
About MorphoSys AG
MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, MorphoSys AG revenues decreased 45% to EUR179.6M. Net loss totaled EUR514.5M vs. income of EUR97.9M. Revenues reflect USA and Canada segment decrease of 51% to EUR156.3M. Net loss reflects Impairment - Goodwill increase from EUR2.1M to EUR230.7M (expense), Other R&D increase of 80% to EUR153.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from EUR3.01 to -EUR15.40.
Equity composition
12/2008, 3-for-1 stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
Semmelweisstr. 7
PLANEGG
BAYERN 82152
DE
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com